临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 2569527-64-4

HM43239

CAS号:2569527-64-4
分子式: C29H33ClN6 分子量: 501.07
产品形式: free base
研发状态: Recruiting
研发用途: Relapsed or Refractory Acute Myeloid Leukemia
研究机构: Aptose Biosciences Inc.
研发日期: March 11 2019
研发阶段: Phase 1 : Phase 2
HM43239 is a novel potent small molecule FLT3 inhibitor that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. IC50s' of HM43239 against FLT3 WT, FLT3 ITD and FLT3 D835Y kinases are 1.1 nM, 1.8 nM and 1.0 nM, respectively.

CAS: 25655-41-8

Povidone iodine

中文名称:聚维酮碘
CAS号:25655-41-8
分子式: (C6H9NO)x.xI2 分子量: N/A
产品形式: free base
研发状态: Withdrawn
研发用途: SARS-CoV-2 Acute Respiratory Disease
研究机构: University of Iowa; 3M
研发日期: July 3 2024
研发阶段: Phase 4
Povidone iodine (Betadine, PVP iodine, PVP-I, Isodine) is a stable chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine. It is used as topical antiseptic in surgery and for skin and mucous membrane infections, also as aerosol.

CAS: 256476-36-5

UK-371804 HCl

CAS号:256476-36-5
分子式: C14H16ClN5O4S.HCl 分子量: 422.29
产品形式: hydrochloride
研发状态: Not yet recruiting
研发用途: Colorectal Cancer
研究机构: University of Chicago
研发日期: Apr-24
研发阶段: Phase 1 : Phase 2
UK-371804 is a potent and selective urokinase-type plasmogen activator (uPA) inhibitor with excellent enzyme potency (Ki=10 nM) and selectivity profile (4000-fold versus tPA and 2700-fold versus plasmin).

CAS: 2563892-44-2

IK-930

CAS号:2563892-44-2
分子式: C19H19F3N4O2S 分子量: 424.44
产品形式: free base
研发状态: Recruiting
研发用途: Solid Tumors Adult; Solid Tumor; Malignant Pleural Mesothelioma (MPM); Epithelioid Hemangioendothelioma (EHE); NF2 Deficient Mesothelioma; Other NF2 Deficient Solid Tumors and Solid Tumors With YAP1/TAZ Fusion Genes; NF2 Deficiency; YAP1 or TAZ Gene Fusions
研究机构: Ikena Oncology
研发日期: January 7 2022
研发阶段: Phase 1
IK-930 is a selective, small-molecule inhibitor of TEAD that prevents palmitate binding and thereby disrupts aberrant TEAD-dependent transcription. IK-930 demonstrates antitumor activity in mouse xenograft models with Hippo pathway genetic alterations.

CAS: 2559761-14-5

garsorasib (D-1553 )

中文名称:7-(2-氨基-6-氟苯基)-1-(4,6-二环丙基嘧啶-5-基)-4-[(2S,5R)-2,5-二甲基-4-丙-2-烯酰哌嗪-1-基]-6-氟嘧啶[2,3-d]嘧啶-2-1
CAS号:2559761-14-5
分子式: C32H32F2N8O2 分子量: 598.65
产品形式: free base
研发状态: Completed
研发用途: Mass Balance Study
研究机构: InventisBio Co. Ltd
研发日期: December 8 2023
研发阶段: Phase 1
Garsorasib (D-1553 ) is a potent and selective oral KRAS^G12C inhibitor with antitumor activity. It has the potential to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC).

CAS: 25526-93-6

3'-Fluoro-3'-deoxythymidine (Alovudine)

中文名称:阿洛夫定
CAS号:25526-93-6
分子式: C10H13FN2O4 分子量: 244.22
产品形式: Free Base
研发状态: Recruiting
研发用途: AML Adult
研究机构: Zhejiang ACEA Pharmaceutical Co. Ltd.
研发日期: December 8 2023
研发阶段: Phase 1
3'-Fluoro-3'-deoxythymidine (Alovudine, CL 184824, FddThd, FLT, MIV-310) is a potent inhibitor of polymerase γ and reverse transcriptase that can be used in the treatment of HIV infection. 3'-Fluoro-3'-deoxythymidine (Alovudine) is also a marker of DNA synthesis that can be used as an early response biomarker in the chemotherapy of pancreatic cancer.